نتایج جستجو برای: cyp3a5

تعداد نتایج: 885  

2017
Lihui Qu Yingying Lu Meike Ying Bingjue Li Chunhua Weng Zhoutao Xie Ludan Liang Chuan Lin Xian Yang Shi Feng Yucheng Wang Xiujin Shen Qin Zhou Ying Chen Zhimin Chen Jianyong Wu Weiqiang Lin Yi Shen Jing Qin Hang Xu Feng Xu Junwen Wang Jianghua Chen Hong Jiang Hongfeng Huang

Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 geno...

Journal: :Transplantation 2011
Nicolas Picard Koukeb Rouguieg-Malki Nassim Kamar Lionel Rostaing Pierre Marquet

BACKGROUND CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics. METHODS We investigated the effect of CYP3A5 6986A>G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients and on its in vitro hepatic me...

2014
Elaine Tseng Robert L. Walsky Ricardo A. Luzietti Jennifer J. Harris Rachel E. Kosa Theunis C. Goosen Michael A. Zientek Scott Obach

Metabolism by cytochrome P4503A (CYP3A) is the most prevalent clearance pathway for drugs. Designation of metabolism by CYP3A commonly refers to the potential contribution by one or both of two enzymes, CYP3A4 and CYP3A5. The metabolic turnover of 32 drugs known to be largely metabolized by CYP3A was examined in human liver microsomes (HLMs) from CYP3A5 expressers (*1/*1 genotype) and nonexpres...

2013
Yoshiyuki Shirasaka Shu-Ying Chang Mary F. Grubb Chi-Chi Peng Kenneth E. Thummel Nina Isoherranen David Rodrigues

This article has not been copyedited and formatted. The final version may differ from this version. Abstract The purpose of this study was to determine the impact of CYP3A5 expression on inhibitory potency (K i or IC 50 values) of CYP3A inhibitors, using recombinant CYP3A4 and CYP3A5 (rCYP3A4 and rCYP3A5) and CYP3A5 genotyped human liver microsomes (HLMs). IC 50 ratios between rCYP3A4-and rCYP3...

Journal: :Pediatric transplantation 2011
Jorge R Ferraris Pablo F Argibay Lucas Costa Graciela Jimenez Paula A Coccia Lidia F R Ghezzi Verónica Ferraris Waldo H Belloso María A Redal Julián M Larriba

  TAC, MMF and MP are used in pediatric kidney tx. The cytochrome P450 (CYP)3A5 enzyme appears to play a role in TAC metabolism. The aims of this study were to investigate CYP3A5 polymorphism's effect on TAC dosing and the age dependency of TAC dosing by testing blood concentrations, and the interaction between steroids and TAC during the first year after tx. Genomic DNA was extracted and ampli...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2012
Ganesh M Mugundu Larry Sallans Yingying Guo Elizabeth A Shaughnessy Pankaj B Desai

Tamoxifen, an antiestrogen used in the prevention and treatment of breast cancer, is extensively metabolized by cytochrome P450 enzymes. Its biotransformation to α-hydroxytamoxifen (α-OHT), which may be genotoxic, and to N-desmethyltamoxifen (N-DMT), which is partially hydroxylated to 4-hydroxy-N-DMT (endoxifen), a potent antiestrogen, is mediated by CYP3A enzymes. However, the potential contri...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2006
Yang Dai Mary F Hebert Nina Isoherranen Connie L Davis Christopher Marsh Danny D Shen Kenneth E Thummel

Previous investigations of solid organ transplant patients treated with tacrolimus showed that individuals carrying a CYP3A5*1 allele have lower dose-adjusted trough blood concentrations compared with homozygous CYP3A5*3 individuals. The objective of this investigation was to quantify the contribution of CYP3A5 to the hepatic and renal metabolic clearance of tacrolimus. Four primary tacrolimus ...

2014
Xiaohai Li Valer Jeso Scott Heyward Gregory S. Walker Raman Sharma Glenn C. Micalizio Michael D. Cameron

Almost half of prescription medications are metabolized by cytochrome P450 3A4 and 3A5. CYP3A4 and 3A5 have significant substrate overlap, and there is currently no way to selectively monitor the activity of these two enzymes, which has led to the erroneous habit of attributing the cumulative activity to CYP3A4. While CYP3A4 expression is ubiquitous, CYP3A5 expression is polymorphic, with large...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2015
Carrie A Vyhlidal Robin E Pearce Roger Gaedigk Justina C Calamia Diana L Shuster Kenneth E Thummel J Steven Leeder

Members of the cytochrome P450 3A (CYP3A) subfamily of drug metabolizing enzymes exhibit developmental changes in expression in human liver characterized by a transition between CYP3A7 and CYP3A4 over the first few years of life. In contrast, the developmental expression of CYP3A5 is less well understood due to polymorphic expression of the enzyme in human tissues as a result of the prevalence ...

Journal: :Drug metabolism and pharmacokinetics 2004
Satoshi Yamaori Hiroshi Yamazaki Shunsuke Iwano Kazuma Kiyotani Keiko Matsumura Goro Honda Kazuko Nakagawa Takashi Ishizaki Tetsuya Kamataki

The purpose of this study was to evaluate a contribution of polymorphic cytochrome P450 (CYP) 3A5 to the oxidation of diltiazem, midazolam and testosterone by liver microsomes from Japanese subjects. Twenty-seven liver samples were classified into three groups according to the CYP3A5 genotypes; CYP3A5(*)1/(*)1 (n=3), (*)1/(*)3 (n=12) and (*)3/(*)3 (n=12). The results of genotyping and immunoche...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید